2 results
Approved WMOCompleted
-To answer the main question *Can we demonstrate a decreased prevalence of fatigue (i.e. a lower score on the fatigue assessment) in patients in complete remission after successful treatment of a gynaecological malignancy, after treatment of a…
Approved WMORecruiting
Primary:Phase I: • To characterize the safety and tolerability and to identify the maximum tolerated dose (MTD) and/or recommended dose (RD) and regimen for future studies of DYP688 as a single agent.Phase Il:• To evaluate the anti-tumor activity of…